Embecta Corp., a health care company headquartered in Franklin Lakes, United States, has been a notable player in the medical supplies and equipment sector. The company specializes in diabetes medication monitoring and delivery equipment, serving a global customer base. Embecta Corp. is publicly traded on the Nasdaq stock exchange, with its shares priced at $5.25 as of August 31, 2026.
The company’s financial metrics reflect its market position and performance. With a market capitalization of approximately $291.23 million, Embecta Corp. has demonstrated resilience in a competitive industry. The price-to-earnings ratio stands at 3.56, indicating investor sentiment and valuation relative to its earnings.
Over the past year, Embecta Corp.’s stock has experienced significant volatility. The 52-week high was recorded at $15.55 on September 16, 2025, while the 52-week low was $2.77 on May 19, 2026. This range highlights the fluctuations in investor confidence and market conditions impacting the company.
Embecta Corp.’s focus on diabetes care solutions positions it strategically within the health care sector, addressing a critical need for effective diabetes management tools. The company’s commitment to innovation and quality in medical supplies continues to drive its operations and customer engagement worldwide.
For further information, stakeholders and interested parties can visit Embecta Corp.’s official website at www.embecta.com .
